Janssen Pharmaceutica NV has identified interleukin-17A (IL-17A)/IL-17 receptor A (IL-17RA) interaction inhibitors reported to be useful for the treatment of psoriasis, rheumatoid arthritis, radiographic axial spondyloarthritis (ankylosing spondylitis), multiple sclerosis, asthma, chronic obstructive pulmonary disease, atopic dermatitis and systemic lupus erythematosus, among others.
McMaster University has synthesized radiolabeled-drug conjugates comprising a glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA)-targeting moiety covalently linked to a DNA intercalating agent through a radiolabeling moiety reported to be useful for diagnosis and treatment of cancer.
Genescience Pharmaceuticals Co. Ltd. has identified phenylalanine hydroxylase (PAH) (R408W mutant) stabilizers reported to be useful for the treatment of phenylketonuria (PKU).
Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized compounds acting as MIR124 activators reported to be useful for the treatment of inflammatory bowel disease and inflammatory disorders.
The U.S. Patent and Trademark Office (PTO) has proposed to limit the use of administrative challenges to patents when the patent in dispute is already the subject of litigation in district court, a change that many in the life sciences might see as an improvement over the current hyper-litigious environment.
Researchers at Dongguk University and Korean Research Institute of Bioscience and Biotechnology have described oxazole derivatives acting as malate dehydrogenase, cytoplasmic (MDH1) and/or malate dehydrogenase, mitochondrial (MDH2) inhibitors reported to be useful for the treatment of cancer.
RSS
